EDSA vs EIKN

Edesa Biotech, Inc. vs Eikon Therapeutics, Inc. — Valuation Comparison 2026

By CirclFi Research Team · Updated 2026-06-03 · Data from SEC EDGAR, FRED & GDELT

Quick Summary — EDSA scores higher on quality with 3.9/10 vs EIKN's 1.7/10. EDSA trades at $6.83 while EIKN trades at $9.60. Both analyzed daily using SEC EDGAR data across 13 institutional models.

EDSA

Biotechnology
Edesa Biotech, Inc.
Quality
3.9
out of 10
Value Trap
24
SAFE
Price
$6.83
Last close
Models
7/13
Active
VS

EIKN

Biotechnology
Eikon Therapeutics, Inc.
Quality
1.7
out of 10
Value Trap
Price
$9.60
Last close
Models
7/13
Active
EDSA
2 models active
Quality 3.9/10 — below average
EIKN
2 models active
Quality 1.7/10 — below average

EDSA vs EIKN — Fair Value Comparison

EDSA
$0$3$5$8 Price$6.83 Bayesian …$2.42 (-64.6%) ML-RIV$0.64 (-90.6%)
EIKN
$0$4$8$11 Price$9.60 Bayesian …$2.50 (-74.0%) PWERM$5.70 (-40.6%)
Market Price Model 1 Model 2

Model-by-Model Comparison

ModelType EDSA Fair ValueEDSA Upside EIKN Fair ValueEIKN Upside
Bayesian DCF Intrinsic $2.42 -64.6% $2.50 -74.0%
First Chicago Scenario $•••.•• ••.•% $•••.•• ••.•%
ML-RIV Intrinsic $0.64 -90.6% $15.18 +58.2%
Dynamic NAV Asset-Based $•••.•• ••.•% $•••.•• ••.•%
PWERM Option-Based $12.44 +82.2% $5.70 -40.6%
Sentiment SOTP Hybrid $•••.•• ••.•% $•••.•• ••.•%
CUCE Ensemble Ensemble $•••.•• ••.•% $•••.•• ••.•%

EDSA vs EIKN — Which Stock Is More Undervalued in 2026?

EDSA scores higher with a 3.9/10 quality rating vs EIKN's 1.7/10. Both stocks are analyzed daily using SEC EDGAR filings across 13 independent models.

How Do EDSA and EIKN Valuations Compare?

At $6.83, EDSA trades +64.6% above its Bayesian DCF fair value of $2.42, while EIKN at $9.60 trades +74.0% above its estimate of $2.50. EIKN shows a wider gap between price and intrinsic value.

Quality of Company: EDSA vs EIKN

EDSA earns a Quality of Company score of 3.9/10 compared to EIKN's 1.7/10. This moderate difference suggests one company has an edge in fundamental quality, though both may offer investment merit depending on valuation. The QOC score synthesizes 32 signals spanning profitability margins, revenue growth, free cash flow, capital allocation, and leverage.

Value Trap Risk: EDSA vs EIKN

Review the value trap analysis for both EDSA and EIKN to assess whether apparent undervaluation reflects genuine opportunity or hidden fundamental risk.

Both in Biotechnology

Both EDSA and EIKN operate in Biotechnology, which has 566 stocks tracked by CirclFi. Same-industry comparisons provide the most direct insight into relative valuation since both companies face similar regulatory environments, market dynamics, and competitive pressures. Both companies are analyzed with models spanning intrinsic (Bayesian DCF, EPV), scenario-based (First Chicago), regime-switching (Markov DDM, RCMH-DCF), machine learning (ML-RIV, FTNN), and ensemble methods (CUCE).

2 of 13 MODELS UNLOCKED

You’re comparing 2 models. 11 more have an opinion.

11 hidden models compare EDSA vs EIKN differently — including EROIC Spread, First Chicago, Markov DDM, PWERM, and 7 more. Some may disagree with the 2 you see above.

11 additional fair values per stock Full confidence breakdown Live terminal — 5,000+ stocks

Bloomberg Terminal: ~$2,000/mo  ·  FactSet: ~$1,000/mo  ·  CirclFi: $0.90/day

See All 13 Models — $0.90/day

We don’t predict prices. We show you what 13 independent mathematical frameworks say a stock is worth — and let you decide.

See all Biotechnology stocks →